UBIO
Asset Logo

Universal Biosensors Inc.

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Universal Biosensors Inc. - Option Exp 08-May-27 Us Person Prohibited Excl Qib

📈 Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.04

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in UBIO

1

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in UBIO

N/A
UBIO investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

100%
👶 Age of investors

18 - 25

26 - 34

35 - 90

100%
🙋 Legal gender of investors

Female

100%

Male

Pearlers who invest in UBIO also invest in...

BetaShares Australian Dividend Harvester Fund (Managed Fund)

HVST

HVST.AX was created on 2014-10-29 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 226.57m in AUM and 54 holdings. HVST.AX aims to provide exposure to large-cap Australian shares, along with the potential for franked income that is at least 1.5x the yield of the Australian broad sharemarket on an annual basis.

🙌 Performance (5Yr p.a)

-1.65%

📊 Share price

$13.76 AUD

🇦🇺 AUSTRALIA

⛳️ DIVERSIFIED

💰 HIGH DIVIDEND

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

🙌 Performance (5Yr p.a)

19.63%

📊 Share price

$61.01 AUD

📈 HIGH PRICE GROWTH

🇺🇸 UNITED STATES

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.

🙌 Performance (5Yr p.a)

-7.03%

📊 Share price

$0.12 AUD

🩺 HEALTH CARE

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

4.35%

📊 Share price

$104.33 AUD

⛳️ DIVERSIFIED

🧱 MATERIALS

💸 FINANCIALS

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.

🩺 HEALTH CARE

Want more shares? Try these...

Urbanise.com Ltd designs and develops cloud-based Software as a Service (SaaS) platform for the property sector, specifically Strata and Facilities Management. The company is headquartered in North Sydney, New South Wales and currently employs 73 full-time employees. The company went IPO on 2014-09-22. Its segments include Strata and Facilities. The company specializes in delivering cutting-edge proptech solutions through its two platforms: Urbanise Strata and Urbanise FM. The Strata platform manages the communications and accounting functions for apartment buildings, strata commercial towers and large housing communities. The Facilities Management platform manages the repair and maintenance for infrastructure, buildings, residential and commercial properties. Urbanise Strata serves strata managers in administering strata schemes and jointly owned properties. Urbanise FM software aids facilities managers in property asset maintenance and contractor supervision. Its client base spans across 17 countries with over 600,000 lots managed on Urbanise Strata and 2.2 million assets managed on Urbanise FM.

🙌 Performance (5Yr p.a)

-7.78%

📊 Share price

$0.44 AUD

🤖 TECHNOLOGY

Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-10. The company specializes in the development and marketing of non-invasive cardiovascular and pulmonary medical devices. The company has three suites of devices in the field of cardiac, vascular, and pulmonary monitoring: the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. The USCOM 1A is a non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities, and is used to guide treatment. The USCOM 1A device has applications in emergency, intensive care medicine and anesthesia. The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms in the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. Its VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators.

🙌 Performance (5Yr p.a)

-15.03%

📊 Share price

$0.03 AUD

🩺 HEALTH CARE

U100.AX was created on 2023-08-21 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 45.44m in AUM and 100 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Global X US 100 Index.

📊 Share price

$14.34 AUD

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.

🙌 Performance (5Yr p.a)

-7.03%

📊 Share price

$0.12 AUD

🩺 HEALTH CARE

Compare
Add to watchlist